Salesforce launches $25B accelerated share repurchase, issues $25B in senior notes

This filing

National Association, and Morgan Stanley & Co. LLC (collectively, the “ASR Counterparties”). Under the terms of the ASR Agreements, the Company will repurchase an aggregate of $25 billion of the Company’s common stock, $0.001 par value per share (such stock, the “Common Stock” ), as part of a share repurchase program (the “Share Repurchase Program”). The Company’s

Comparable filing

On May 7, 2026, ProPetro Holding Corp. (the “ Company ”), issued $690 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2031

This filing

On March 11, 2026, Salesforce, Inc. (the “Company” or “Salesforce”) entered into accelerated share repurchase agreements (the “ASR Agreements”) with Banco Santander, S.A., Bank of America, N.A., Citibank, N.A., JPMorgan Chase Bank, National Association, and Morgan Stanley & Co. LLC (collectively, the “ASR Counterparties”). Under the terms of the ASR Agreements, the Company will repurchase an aggregate of $25 billion of the Company’s common stock

Comparable filing

On May 28, 2026, the Company, as parent, Trinseo NA Finance LLC, as holdings, Trinseo Luxco Finance SPV S.à r.l. and Trinseo NA Finance SPV LLC (together, the “ SHC Borrowers ”), as borrowers, the guarantors party thereto from time to time, the lenders party thereto from time to time (the “ SHC DIP Lenders ”), and Alter Domus (US) LLC, as administrative agent and collateral agent, entered into a Senior Secured Super-Priority Debtor-In-Possession HoldCo Credit Agreement (the “ Super-Holdco DIP Credit Agreement ”), providing for a senior secured super-priority priming term loan debtor-in-possession credit facility in an aggregate principal amount of $157.5 million (the “ Super-Holdco DIP Facility ”).

This filing

National Association, and Morgan Stanley & Co. LLC (collectively, the “ASR Counterparties”). Under the terms of the ASR Agreements, the Company will repurchase an aggregate of $25 billion of the Company’s common stock, $0.001 par value per share (such stock, the “Common Stock” ), as part of a share repurchase program (the “Share Repurchase Program”). The Company’s

Comparable filing

On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).

This filing

On March 11, 2026, Salesforce, Inc. (the “Company” or “Salesforce”) entered into accelerated share repurchase agreements (the “ASR Agreements”) with Banco Santander, S.A., Bank of America, N.A., Citibank, N.A., JPMorgan Chase Bank, National Association, and Morgan Stanley & Co. LLC (collectively, the “ASR Counterparties”). Under the terms of the ASR Agreements, the Company will repurchase an aggregate of $25 billion of the Company’s common stock

Comparable filing

On May 11, 2026, Accendra Health, Inc. (the “ Company ”) entered into a Commitment and Consent Letter (the “ Commitment Letter ”) with certain institutions that are (a)(i) holders of the Company’s 4.500% Senior Notes due 2029 (the “ 2029 Notes ”) and 6.625% Senior Notes due 2030 (the “ 2030 Notes ” and, together with the 2029 Notes, the “ Existing Notes ”), collectively holding approximately all of the outstanding principal amount of the 2029 Notes and approximately 83% of the outstanding principal amount of the 2030 Notes as of May 11, 2026 and (ii) lenders under the Company’s existing Term Loan Credit Agreement (as defined below) (collectively, the “ Commitment and Consenting Parties ” and each, a “ Commitment and Consenting Party ”), (b) certain lenders under the Company’s existing Term Loan Credit Agreement consenting solely with respect to the Term B-1 Term Loan Consent (as defined below) (the “ Term B-1 Term Loan Consenting Parties ”) and (c) all lenders under the Company’s Exist

This filing

National Association, and Morgan Stanley & Co. LLC (collectively, the “ASR Counterparties”). Under the terms of the ASR Agreements, the Company will repurchase an aggregate of $25 billion of the Company’s common stock, $0.001 par value per share (such stock, the “Common Stock” ), as part of a share repurchase program (the “Share Repurchase Program”). The Company’s

Comparable filing

NW Corp's obligations under the Term Loan are secured by a $225 million first mortgage bond

This filing

National Association, and Morgan Stanley & Co. LLC (collectively, the “ASR Counterparties”). Under the terms of the ASR Agreements, the Company will repurchase an aggregate of $25 billion of the Company’s common stock, $0.001 par value per share (such stock, the “Common Stock” ), as part of a share repurchase program (the “Share Repurchase Program”). The Company’s

Comparable filing

Item 1.01. Entry into a Material Definitive Agreement. On May 27, 2026 (the " Closing Date "), BlackRock TCP Capital Corp. (the " Company "), through its subsidiary, completed a $535,780,000 securitization of certain loans held by a subsidiary of the Company (the " CLO Transaction "). On the Closing Date and in connection with the CLO Transaction, BlackRock DLF 2026-C

This filing

National Association, and Morgan Stanley & Co. LLC (collectively, the “ASR Counterparties”). Under the terms of the ASR Agreements, the Company will repurchase an aggregate of $25 billion of the Company’s common stock, $0.001 par value per share (such stock, the “Common Stock” ), as part of a share repurchase program (the “Share Repurchase Program”). The Company’s

Comparable filing

On May 29, 2026, Encompass Health Corporation (the “Company”) completed the issuance and sale of $500 million in aggregate principal amount of its 5.875% Senior Notes due 2034 (the “Notes”), along with the related guarantees of the Notes by certain of the Company’s subsidiaries (the “Guarantees”), in a private offering.

This filing

National Association, and Morgan Stanley & Co. LLC (collectively, the “ASR Counterparties”). Under the terms of the ASR Agreements, the Company will repurchase an aggregate of $25 billion of the Company’s common stock, $0.001 par value per share (such stock, the “Common Stock” ), as part of a share repurchase program (the “Share Repurchase Program”). The Company’s

Comparable filing

The Amendment provides for, among other things, a new tranche of term loans under the Credit Agreement in an aggregate original principal amount of $868,522,978.38 (the “New Term Loans”), which New Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Amendment), as further set forth in the Amendment. The New Term Loans mature on December 6, 2030.